|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miller KD, Nogueira L, Mariotto AB,
Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel
RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J
Clin. 69:363–385. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Das PK, Pillai S, Rakib MA, Khanam JA,
Gopalan V, Lam AKY and Islam F: Plasticity of cancer stem cell:
Origin and role in disease progression and therapy resistance. Stem
Cell Rev Rep. 16:397–412. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuşoğlu A and Avcı ÇB: Cancer stem cells:
A brief review of the current status. Gene. 681:80–85. 2019.
View Article : Google Scholar
|
|
5
|
Yadav AK and Desai NS: Cancer stem cells:
Acquisition, characteristics, therapeutic implications, targeting
strategies and future prospects. Stem Cell Rev Rep. 15:331–355.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bakhshinyan D, Adile AA, Qazi MA, Singh M,
Kameda-Smith MM, Yelle N, Chokshi C, Venugopal C and Singh SK:
Introduction to cancer stem cells: Past, present, and future.
Methods Mol Biol. 1692:1–16. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Batlle E and Clevers H: Cancer stem cells
revisited. Nat Med. 23:1124–1134. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee SH, Reed-Newman T, Anant S and
Ramasamy TS: Regulatory role of quiescence in the biological
function of cancer stem cells. Stem Cell Rev Rep. 16:1185–1207.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Najafi M, Mortezaee K and Majidpoor J:
Cancer stem cell (CSC) resistance drivers. Life Sci.
234:1167812019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Steinbichler TB, Dudas J, Skvortsov S,
Ganswindt U, Riechelmann H and Skvortsova II: Therapy resistance
mediated by cancer stem cells. Semin Cancer Biol. 53:156–167. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou JM, Hu SQ, Jiang H, Chen YL, Feng JH,
Chen ZQ and Wen KM: OCT4B1 promoted EMT and regulated the
self-renewal of CSCs in CRC: Effects associated with the balance of
miR-8064/PLK1. Mol Ther Oncolytics. 15:7–20. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Geuens T, Bouhy D and Timmerman V: The
hnRNP family: Insights into their role in health and disease. Hum
Genet. 135:851–867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang TH, Chen CC, Hsiao YC, Lin YH, Pi WC,
Huang PR, Wang TCV and Chen CY: Heterogeneous nuclear
ribonucleoproteins A1 and A2 function in telomerase-dependent
maintenance of telomeres. Cancers (Basel). 11:3342019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Weighardt F, Biamonti G and Riva S: The
roles of heterogeneous nuclear ribonucleoproteins (hnRNP) in RNA
metabolism. Bioessays. 18:747–756. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Han SP, Tang YH and Smith R: Functional
diversity of the hnRNPs: Past, present and perspectives. Biochem J.
430:379–392. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xuan Y, Wang J, Ban L, Lu JJ, Yi C, Li Z,
Yu W, Li M, Xu T, Yang W, et al: hnRNPA2/B1 activates
cyclooxygenase-2 and promotes tumor growth in human lung cancers.
Mol Oncol. 10:610–624. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu Y, Sun Z, Deng J, Hu B, Yan W, Wei H
and Jiang J: Splicing factor hnRNPA2B1 contributes to tumorigenic
potential of breast cancer cells through STAT3 and ERK1/2 signaling
pathway. Tumour Biol. 39:10104283176943182017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shi X, Ran L, Liu Y, Zhong SH, Zhou PP,
Liao MX and Fang W: Knockdown of hnRNP A2/B1 inhibits cell
proliferation, invasion and cell cycle triggering apoptosis in
cervical cancer via PI3K/AKT signaling pathway. Oncol Rep.
39:939–950. 2018.PubMed/NCBI
|
|
19
|
Ma Y, Yang L and Li R: HnRNPA2/B1 is a
novel prognostic biomarker for breast cancer patients. Genet Test
Mol Biomarkers. 24:701–707. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yin D, Kong C and Chen M: Effect of
hnRNPA2/B1 on the proliferation and apoptosis of glioma U251 cells
via the regulation of AKT and STAT3 pathways. Biosci Rep.
40:BSR201903182020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou JM, Jiang H, Yuan T, Zhou GX, Li XB
and Wen KM: High hnRNP AB expression is associated with poor
prognosis in patients with colorectal cancer. Oncol Lett.
18:6459–6468. 2019.PubMed/NCBI
|
|
22
|
Zhou ZJ, Dai Z, Zhou SL, Hu ZQ, Chen Q,
Zhao YM, Shi YH, Gao Q, Wu WZ, Qiu SJ, et al: HNRNPAB induces
epithelial-mesenchymal transition and promotes metastasis of
hepatocellular carcinoma by transcriptionally activating SNAIL.
Cancer Res. 74:2750–2762. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tauler J, Zudaire E, Liu H, Shih J and
Mulshine JL: hnRNP A2/B1 modulates epithelial-mesenchymal
transition in lung cancer cell lines. Cancer Res. 70:7137–7147.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dai S, Zhang J, Huang S, Lou B, Fang B, Ye
T, Huang X, Chen B and Zhou M: HNRNPA2B1 regulates the
epithelial-mesenchymal transition in pancreatic cancer cells
through the ERK/snail signalling pathway. Cancer Cell Int.
17:122017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shibue T and Weinberg RA: EMT, CSCs, and
drug resistance: The mechanistic link and clinical implications.
Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cai Z, Cao Y, Luo Y, Hu H and Ling H:
Signalling mechanism(s) of epithelial-mesenchymal transition and
cancer stem cells in tumour therapeutic resistance. Clin Chim Acta.
483:156–163. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nishiyama M, Tsunedomi R, Yoshimura K,
Hashimoto N, Matsukuma S, Ogihara H, Kanekiyo S, Iida M, Sakamoto
K, Suzuki N, et al: Metastatic ability and the
epithelial-mesenchymal transition in induced cancer stem-like
hepatoma cells. Cancer Sci. 109:1101–1109. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stockley J, Villasevil ME, Nixon C, Ahmad
I, Leung HY and Rajan P: The RNA-binding protein hnRNPA2 regulates
β-catenin protein expression and is overexpressed in prostate
cancer. RNA Biol. 11:755–765. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Meng X, Cui J, Wang Y, Zhang X, Li D, Hai
Y and Du H: Heterogeneous nuclear ribonucleoprotein A1 interacts
with microRNA-34a to promote chondrogenic differentiation of
mesenchymal stem cells. Am J Transl Res. 9:1774–1782.
2017.PubMed/NCBI
|
|
30
|
Jiang S, Song C, Gu X, Wang M, Miao D, Lv
J and Liu Y: Ubiquitin-specific peptidase 22 contributes to
colorectal cancer stemness and chemoresistance via Wnt/β-catenin
pathway. Cell Physiol Biochem. 46:1412–1422. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cheng X, Xu X, Chen D, Zhao F and Wang W:
Therapeutic potential of targeting the Wnt/β-catenin signaling
pathway in colorectal cancer. Biomed Pharmacother. 110:473–481.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Martin-Orozco E, Sanchez-Fernandez A,
Ortiz-Parra I and Ayala-San Nicolas M: WNT signaling in tumors: The
way to evade drugs and immunity. Front Immunol. 10:28542019.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tang T, Guo C, Xia T, Zhang R, Zen K, Pan
Y and Jin L: LncCCAT1 promotes breast cancer stem cell function
through activating WNT/β-catenin signaling. Theranostics.
9:7384–7402. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yao Q, Chen Y and Zhou X: The roles of
microRNAs in epigenetic regulation. Curr Opin Chem Biol. 51:11–17.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Saliminejad K, Khorram Khorshid HR,
Soleymani Fard S and Ghaffari SH: An overview of microRNAs:
Biology, functions, therapeutics, and analysis methods. J Cell
Physiol. 234:5451–5465. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu XM, Fu Q, Du Y, Yang YX and Cho WC:
MicroRNA as regulators of cancer stem cells and chemoresistance in
colorectal cancer. Curr Cancer Drug Targets. 16:738–754. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Guo JC, Yang YJ, Zhang JQ, Guo M, Xiang L,
Yu SF, Ping H and Zhuo L: MicroRNA-448 inhibits stemness
maintenance and self-renewal of hepatocellular carcinoma stem cells
through the MAGEA6-mediated AMPK signaling pathway. J Cell Physiol.
234:23461–23474. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jiang S, Miao D, Wang M, Lv J, Wang Y and
Tong J: miR-30-5p suppresses cell chemoresistance and stemness in
colorectal cancer through USP22/Wnt/β-catenin signaling axis. J
Cell Mol Med. 23:630–640. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mukohyama J, Isobe T, Hu Q, Hayashi T,
Watanabe T, Maeda M, Yanagi H, Qian X, Yamashita K, Minami H, et
al: miR-221 targets QKI to enhance the tumorigenic capacity of
human colorectal cancer stem cells. Cancer Res. 79:5151–5158. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cheng CW, Liao WL, Chen PM, Yu JC, Shiau
HP, Hsieh YH, Lee HJ, Cheng YC, Wu PE and Shen CY: miR-139
modulates cancer stem cell function of human breast cancer through
targeting CXCR4. Cancers (Basel). 13:25822021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ni H, Qin H, Sun C, Liu Y, Ruan G, Guo Q,
Xi T, Xing Y and Zheng L: miR-375 reduces the stemness of gastric
cancer cells through triggering ferroptosis. Stem Cell Res Ther.
12:3252021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Naito S, von Eschenbach AC, Giavazzi R and
Fidler IJ: Growth and metastasis of tumor cells isolated from a
human renal cell carcinoma implanted into different organs of nude
mice. Cancer Res. 46:4109–4115. 1986.PubMed/NCBI
|
|
44
|
Gupta R, Bhatt LK, Johnston TP and
Prabhavalkar KS: Colon cancer stem cells: Potential target for the
treatment of colorectal cancer. Cancer Biol Ther. 20:1068–1082.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wen K, Fu Z, Wu X, Feng J, Chen W and Qian
J: Oct-4 is required for an antiapoptotic behavior of
chemoresistant colorectal cancer cells enriched for cancer stem
cells: Effects associated with STAT3/Survivin. Cancer Lett.
333:56–65. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lin QY, Wang JQ, Wu LL, Zheng WE and Chen
PR: miR-638 represses the stem cell characteristics of breast
cancer cells by targeting E2F2. Breast Cancer. 27:147–158. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Erdogan S and Turkekul K: Neferine
inhibits proliferation and migration of human prostate cancer stem
cells through p38 MAPK/JNK activation. J Food Biochem.
44:e132532020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Abbaszadegan MR, Bagheri V, Razavi MS,
Momtazi AA, Sahebkar A and Gholamin M: Isolation, identification,
and characterization of cancer stem cells: A review. J Cell
Physiol. 232:2008–2018. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bhutia SK, Naik PP, Praharaj PP, Panigrahi
DP, Bhol CS, Mahapatra KK, Saha S and Patra S: Identification and
characterization of stem cells in oral cancer. Methods Mol Biol.
2002:129–139. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang C, Xie J, Guo J, Manning HC, Gore JC
and Guo N: Evaluation of CD44 and CD133 as cancer stem cell markers
for colorectal cancer. Oncol Rep. 28:1301–1308. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zahran AM, Rayan A, Fakhry H, Attia AM,
Ashmawy AM, Soliman A, Elkady A and Hetta HF: Pretreatment
detection of circulating and tissue CD133(+) CD44(+) cancer stem
cells as a prognostic factor affecting the outcomes in Egyptian
patients with colorectal cancer. Cancer Manag Res. 11:1237–1248.
2019. View Article : Google Scholar : PubMed/NCBI
|
